Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Laparoscopic Parenchymal-Sparing Hepatectomy for Multiple Colorectal Liver Metastases Improves Outcomes and Salvageability: A Propensity Score-Matched Analysis.

Okumura S, Tabchouri N, Leung U, Tinguely P, Louvet C, Beaussier M, Gayet B, Fuks D.

Ann Surg Oncol. 2019 Oct 11. doi: 10.1245/s10434-019-07902-x. [Epub ahead of print]

PMID:
31605335
2.

Perioperative and long-term outcomes of laparoscopic liver resections for non-colorectal liver metastases.

Triantafyllidis I, Gayet B, Tsiakyroudi S, Tabchouri N, Beaussier M, Bennamoun M, Sarran A, Lefevre M, Louvet C, Fuks D.

Surg Endosc. 2019 Oct 4. doi: 10.1007/s00464-019-07148-4. [Epub ahead of print]

PMID:
31586246
3.

[Olaparib and pancreatic cancer: A challenging Lesson].

Louvet C, Samalin E, Michel P.

Bull Cancer. 2019 Sep;106(9):715-716. doi: 10.1016/j.bulcan.2019.07.002. Epub 2019 Aug 6. French. No abstract available.

PMID:
31399206
4.

Erratum to 'Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)' [Eur J Cancer 107 (January 2019) 46-52].

Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C.

Eur J Cancer. 2019 Sep;118:190. doi: 10.1016/j.ejca.2019.06.004. Epub 2019 Jul 19. No abstract available.

PMID:
31331779
5.

Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

Phelip JM, Tougeron D, Léonard D, Benhaim L, Desolneux G, Dupré A, Michel P, Penna C, Tournigand C, Louvet C, Christou N, Chevallier P, Dohan A, Rousseaux B, Bouché O.

Dig Liver Dis. 2019 Oct;51(10):1357-1363. doi: 10.1016/j.dld.2019.05.035. Epub 2019 Jul 15. Review.

PMID:
31320305
6.

Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.

Charton E, Bachet JB, Hammel P, Desramé J, Chibaudel B, Cohen R, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Guerin-Meyer V, Taieb J, Volet J, Louvet C, Anota A, Bonnetain F.

Cancer Med. 2019 Sep;8(11):5079-5088. doi: 10.1002/cam4.2311. Epub 2019 Jul 17.

7.

Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials.

Auclin E, Taieb J, Lepage C, Aparicio T, Faroux R, Mini E, Folprecht G, Salazar R, Benetkiewicz M, Banzi M, Louvet C, Van Laethem JL, Tabernero J, Hickish T, de Gramont A, André T, Vernerey D.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1153-1161. doi: 10.1158/1055-9965.EPI-18-0867.

PMID:
31263053
8.

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation.

Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, Louvet C, Vanhove B, Floto RA, Anegon I, Cuturi MC, Girotti MR, Rabinovich GA, Hill M.

Cancer Cell. 2019 May 13;35(5):767-781.e6. doi: 10.1016/j.ccell.2019.04.003.

9.

[A GERCOR-AERIO national survey of oncology residents in France: Current setting and expectations regarding post-internship and research].

Hilmi M, Rousseau B, Cohen R, Vienot A, Vernerey D, Bartholin L, Blanc-Durand F, Louvet C, Turpin A, Neuzillet C.

Bull Cancer. 2019 May;106(5):407-420. doi: 10.1016/j.bulcan.2019.02.009. Epub 2019 Apr 12. French.

PMID:
30987751
10.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.

Cabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C.

Cancers (Basel). 2019 Mar 21;11(3). pii: E396. doi: 10.3390/cancers11030396.

11.

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.

Chibaudel B, Bachet JB, André T, Auby D, Desramé J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V, Dauba J, Lledo G, Garcia ML, Dubreuil O, Hamed NB, Meurisse A, Larsen AK, Tijeras-Raballand A, Bonnetain F, De Gramont A.

Int J Oncol. 2019 Apr;54(4):1433-1445. doi: 10.3892/ijo.2019.4709. Epub 2019 Feb 1.

PMID:
30720091
12.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM.

J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.

PMID:
30707660
13.

After laparoscopic liver resection for colorectal liver metastases, age does not influence morbi-mortality.

Zarzavadjian Le Bian A, Tabchouri N, Bennamoun M, Louvet C, Tubbax C, Sarran A, Lefevre M, Beaussier M, Pamoukdjian F, Wind P, Gayet B, Fuks D.

Surg Endosc. 2019 Nov;33(11):3704-3710. doi: 10.1007/s00464-019-06663-8. Epub 2019 Jan 22.

PMID:
30671669
14.

Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).

Watson S, de la Fouchardière C, Kim S, Cohen R, Bachet JB, Tournigand C, Ferraz JM, Lefevre M, Colin D, Svrcek M, Meurisse A, Louvet C.

Eur J Cancer. 2019 Jan;107:46-52. doi: 10.1016/j.ejca.2018.11.006. Epub 2018 Dec 7. Erratum in: Eur J Cancer. 2019 Sep;118:190.

PMID:
30529902
15.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.

Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O.

Gastric Cancer. 2019 May;22(3):577-586. doi: 10.1007/s10120-018-0885-z. Epub 2018 Oct 11.

PMID:
30311042
16.

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.

Fenioux C, Louvet C, Charton E, Rozet F, Ropert S, Prapotnich D, Barret E, Sanchez-Salas R, Mombet A, Cathala N, Joulia ML, Molitor JL, Henriques J, Bonnetain F, Cathelineau X, Bennamoun M.

BJU Int. 2019 Feb;123(2):300-306. doi: 10.1111/bju.14511. Epub 2018 Sep 4.

PMID:
30099821
17.

Recurrence patterns after laparoscopic resection of colorectal liver metastases.

Tabchouri N, Gayet B, Okumura S, Donatelli G, Beaussier M, Bennamoun M, Louvet C, Fuks D.

Surg Endosc. 2018 Dec;32(12):4788-4797. doi: 10.1007/s00464-018-6229-6. Epub 2018 May 14.

PMID:
29761279
18.

Specific features of colorectal cancer in patients with metabolic syndrome: a matched case-control analysis of 772 patients.

Zarzavadjian Le Bian A, Denet C, Tabchouri N, Donatelli G, Wind P, Louvet C, Bennamoun M, Christidis C, Perniceni T, Fuks D, Gayet B.

Langenbecks Arch Surg. 2018 Jun;403(4):443-450. doi: 10.1007/s00423-018-1677-y. Epub 2018 Apr 27.

PMID:
29704123
19.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER.

J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.

PMID:
29620995
20.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.

PMID:
29409778
21.

Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses.

Lopez Robles MD, Pallier A, Huchet V, Le Texier L, Remy S, Braudeau C, Delbos L, Moreau A, Louvet C, Brosseau C, Royer PJ, Magnan A, Halary F, Josien R, Cuturi MC, Anegon I, Chiffoleau E.

Blood Adv. 2017 Mar 22;1(9):557-568. doi: 10.1182/bloodadvances.2016002360. eCollection 2017 Mar 28.

22.

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.

Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A.

Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24.

23.

Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Lupinacci RM, Goloudina A, Buhard O, Bachet JB, Maréchal R, Demetter P, Cros J, Bardier-Dupas A, Collura A, Cervera P, Scriva A, Dumont S, Hammel P, Sauvanet A, Louvet C, Delpéro JR, Paye F, Vaillant JC, André T, Closset J, Emile JF, Van Laethem JL, Jonchère V, Abd Alsamad I, Antoine M, Rodenas A, Fléjou JF, Dusetti N, Iovanna J, Duval A, Svrcek M.

Gastroenterology. 2018 Mar;154(4):1061-1065. doi: 10.1053/j.gastro.2017.11.009. Epub 2017 Nov 20.

PMID:
29158190
24.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.

BMC Cancer. 2017 Aug 25;17(1):574. doi: 10.1186/s12885-017-3566-0.

25.

[Clinical research activity of the French cancer cooperative network: Overview and perspectives].

Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz JF, Girault C, Salles G, Haioun C, Deschaseaux P, Casassus P, Mathiot C, Pujade-Lauraine É, Votan B, Louvet C, Delpeut C, Bardet É, Vintonenko N, Hoang Xuan K, Vo M, Michon J, Milleron B.

Bull Cancer. 2017 Jul - Aug;104(7-8):652-661. doi: 10.1016/j.bulcan.2017.05.006. Epub 2017 Jul 5. French.

PMID:
28688747
26.

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.

Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.

Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346. doi: 10.1016/S2468-1253(17)30046-8. Epub 2017 Feb 28.

PMID:
28397697
27.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx037.

PMID:
28383673
28.

Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation.

Martin JC, Wolk K, Bériou G, Abidi A, Witte-Händel E, Louvet C, Kokolakis G, Drujont L, Dumoutier L, Renauld JC, Sabat R, Josien R.

J Immunol. 2017 May 1;198(9):3671-3678. doi: 10.4049/jimmunol.1700021. Epub 2017 Mar 29.

29.

Time course of Graves' orbitopathy after total thyroidectomy and radioiodine therapy for thyroid cancer.

Louvet C, De Bellis A, Pereira B, Bournaud C, Kelly A, Maqdasy S, Roche B, Desbiez F, Borson-Chazot F, Tauveron I, Batisse-Lignier M.

Medicine (Baltimore). 2016 Nov;95(48):e5474.

30.

[Are cancer outpatients ready for e-medicine?]

Kempf E, Prévost A, Rousseau B, Macquin-Mavier I, Louvet C, Tournigand C.

Bull Cancer. 2016 Oct;103(10):841-848. doi: 10.1016/j.bulcan.2016.06.004. Epub 2016 Aug 3. French.

PMID:
27497498
31.

Comparative Study of the Immunoregulatory Capacity of In Vitro Generated Tolerogenic Dendritic Cells, Suppressor Macrophages, and Myeloid-Derived Suppressor Cells.

Carretero-Iglesia L, Bouchet-Delbos L, Louvet C, Drujont L, Segovia M, Merieau E, Chiffoleau E, Josien R, Hill M, Cuturi MC, Moreau A.

Transplantation. 2016 Oct;100(10):2079-2089.

PMID:
27653226
32.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP).

Vernerey D, Huguet F, Vienot A, Goldstein D, Paget-Bailly S, Van Laethem JL, Glimelius B, Artru P, Moore MJ, André T, Mineur L, Chibaudel B, Benetkiewicz M, Louvet C, Hammel P, Bonnetain F.

Br J Cancer. 2016 Jul 26;115(3):281-9. doi: 10.1038/bjc.2016.212. Epub 2016 Jul 12.

33.

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

Hamidou Z, Chibaudel B, Hebbar M, Hug de Larauze M, André T, Louvet C, Brusquant D, Garcia-Larnicol ML, de Gramont A, Bonnetain F.

PLoS One. 2016 Jun 16;11(6):e0157067. doi: 10.1371/journal.pone.0157067. eCollection 2016.

34.

Generation of a Double KO Mouse by Simultaneous Targeting of the Neighboring Genes Tmem176a and Tmem176b Using CRISPR/Cas9: Key Steps from Design to Genotyping.

Lemoine A, Chauveau-Le Friec G, Langa F, Louvet C.

J Genet Genomics. 2016 May 20;43(5):329-40. doi: 10.1016/j.jgg.2016.04.004. Epub 2016 Apr 22.

PMID:
27234594
35.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group.

JAMA. 2016 May 3;315(17):1844-53. doi: 10.1001/jama.2016.4324.

PMID:
27139057
36.

Infundibuloneurohypophysitis Associated With Sjögren Syndrome Successfully Treated With Mycophenolate Mofetil: A Case Report.

Louvet C, Maqdasy S, Tekath M, Grobost V, Rieu V, Ruivard M, Le Guenno G.

Medicine (Baltimore). 2016 Mar;95(13):e3132. doi: 10.1097/MD.0000000000003132.

37.

RORγt+ cells selectively express redundant cation channels linked to the Golgi apparatus.

Drujont L, Lemoine A, Moreau A, Bienvenu G, Lancien M, Cens T, Guillot F, Bériou G, Bouchet-Delbos L, Fehling HJ, Chiffoleau E, Nicot AB, Charnet P, Martin JC, Josien R, Cuturi MC, Louvet C.

Sci Rep. 2016 Mar 24;6:23682. doi: 10.1038/srep23682.

38.

Outcomes of Laparoscopic Liver Resection for Patients with Large Colorectal Liver Metastases: A Case-Matched Analysis.

Nomi T, Fuks D, Louvet C, Nakajima Y, Gayet B.

World J Surg. 2016 Jul;40(7):1702-8. doi: 10.1007/s00268-016-3467-4.

PMID:
27000874
39.

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY, Bidard FC.

Mol Oncol. 2016 Mar;10(3):481-93. doi: 10.1016/j.molonc.2016.01.006. Epub 2016 Jan 22. Review.

40.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

41.

Second and Third Laparoscopic Liver Resection for Patients With Recurrent Colorectal Liver Metastases.

Nomi T, Fuks D, Ogiso S, Nakajima Y, Louvet C, Gayet B.

Ann Surg. 2016 May;263(5):e68-72. doi: 10.1097/SLA.0000000000001528. No abstract available.

PMID:
26641255
42.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776
43.

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A.

Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26474518
44.

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Bachet JB, Chibaudel B, Bonnetain F, Validire P, Hammel P, André T, Louvet C; GERCOR group.

BMC Cancer. 2015 Oct 6;15:653. doi: 10.1186/s12885-015-1656-4.

45.

Laparoscopic two-stage hepatectomy for bilobar colorectal liver metastases.

Fuks D, Nomi T, Ogiso S, Gelli M, Velayutham V, Conrad C, Louvet C, Gayet B.

Br J Surg. 2015 Dec;102(13):1684-90. doi: 10.1002/bjs.9945. Epub 2015 Sep 22.

PMID:
26392212
46.

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

Ménager J, Gorin JB, Maurel C, Drujont L, Gouard S, Louvet C, Chérel M, Faivre-Chauvet A, Morgenstern A, Bruchertseifer F, Davodeau F, Gaschet J, Guilloux Y.

PLoS One. 2015 Jun 22;10(6):e0130249. doi: 10.1371/journal.pone.0130249. eCollection 2015.

47.

Reply to E.C. Smyth et al and E. Elimova et al.

Guimbaud R, Louvet C, Ychou M, Bouché O, Rougier P.

J Clin Oncol. 2015 Jul 20;33(21):2410-1. doi: 10.1200/JCO.2014.60.5550. Epub 2015 Jun 15. No abstract available.

PMID:
26077234
48.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

Hebbar M, Chibaudel B, André T, Mineur L, Smith D, Louvet C, Dutel JL, Ychou M, Legoux JL, Mabro M, Faroux R, Auby D, Brusquant D, Khalil A, Truant S, Hadengue A, Dalban C, Gayet B, Paye F, Pruvot FR, Bonnetain F, de Gramont A; Group Coopérateur Multidisciplinaire en Oncologie (GERCOR) Group.

Ann Oncol. 2015 May;26(5):1040. doi: 10.1093/annonc/mdv141. No abstract available.

PMID:
25900678
49.

Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma.

Simon M, Mal F, Perniceni T, Ferraz JM, Strauss C, Levard H, Louvet C, Fuks D, Gayet B.

Dis Esophagus. 2016 Apr;29(3):236-40. doi: 10.1111/dote.12332. Epub 2015 Mar 10.

PMID:
25758761
50.

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

Soularue É, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, Hentic O, Samalin E, Chibaudel B, de Gramont A, André T; for GERCOR.

Bull Cancer. 2015 Apr;102(4):324-31. doi: 10.1016/j.bulcan.2014.08.001. Epub 2015 Mar 3.

PMID:
25744576

Supplemental Content

Loading ...
Support Center